Schwarz H, Bässler S, Balta D, Socher E, Zunke F, Arnold P (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 433
Article Number: 113977
DOI: 10.1016/j.bbr.2022.113977
Parkinson's disease (PD) is a progressive neurological disorder marked by cardinal clinical symptoms such as rigor, tremor, and akinesia. Albeit a loss of dopaminergic neurons from the substantia nigra pars compacta is causative for the movement impairments found in patients, molecular reasoning for this loss is still incomplete. In recent years, triggering factor expressed on myeloid cells (TREM2) gained attention in the field of neurodegeneration as it could be associated with different neurodegenerative disorders. Primarily identified as a risk factor in Alzheimer's disease, variants in TREM2 were linked to PD and multiple sclerosis, too. Expressed on phagocytic cells, such as macrophages and microglia, TREM2 puts the focus on inflammation associated conditions in PD and provides a molecular target that could at least partly explain the role of immune cells in PD. Here, we summarize expression patterns and molecular functions of TREM2, recapitulate on its role in inflammation, phagocytosis and cell survival, before turning to neurodegenerative disorders with an emphasis on PD.
APA:
Schwarz, H., Bässler, S., Balta, D., Socher, E., Zunke, F., & Arnold, P. (2022). The role of triggering receptor expressed on myeloid cells 2 in Parkinson's disease and other neurodegenerative disorders. Behavioural Brain Research, 433. https://dx.doi.org/10.1016/j.bbr.2022.113977
MLA:
Schwarz, Hannah, et al. "The role of triggering receptor expressed on myeloid cells 2 in Parkinson's disease and other neurodegenerative disorders." Behavioural Brain Research 433 (2022).
BibTeX: Download